贾纳斯激酶
托法替尼
类风湿性关节炎
STAT蛋白
斯达
JAK-STAT信号通路
医学
癌症研究
鲁索利替尼
免疫学
免疫系统
激酶
信号转导
受体
车站3
生物
细胞因子
内科学
酪氨酸激酶
遗传学
骨髓
骨髓纤维化
作者
Abdolkarim Hosseini,Tohid Gharibi,Faroogh Marofi,Mahsa Javadian,Zohreh Babaloo,Behzad Baradaran
摘要
Abstract Many cytokines are crucial drivers of cancers and autoimmune conditions. These proteins bind to receptors and signal their responses through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Genetic variations in the JAK–STAT pathway are correlated with the increased risk of cancers, autoimmunity as well as inflammatory diseases. Targeting JAKs and STATs can be a safe and efficacious strategy for treating these diseases. Tofacitinib, as the first JAK inhibitor, is approved for rheumatoid arthritis therapy. Also, many other JAK inhibitors have been proven or are in various phases of clinical trials for various diseases. At present, small‐molecule JAK inhibitors are considered as a novel category of drugs in the treatment of cancer and immune‐mediated diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI